^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Mantle Cell Lymphoma
    Drug:Rituxan (rituximab) (CD20 inhibitor) +
    Calquence (acalabrutinib) (BTK inhibitor) +
    bendamustine (DNA replication inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Title:

    FDA approves acalabrutinib with bendamustine and rituximab for previously untreated mantle cell lymphoma

    Published date:
    01/16/2025
    Excerpt:
    On January 16, 2025, the Food and Drug Administration granted traditional approval to acalabrutinib (Calquence, AstraZeneca) with bendamustine and rituximab for adults with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT).
    Trial ID:
    ACE-LY-308